Laboratory:Hachioji
Laboratory:Hachioji
○antiepileptic drug
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
BLOOD COLLECTION TIME |
---|---|---|---|---|---|---|---|---|
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
4-12(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.5 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
4-12(μg/mL) | Immediately before next administration (Trough concentration) | |
Clonazepam
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
20-70(ng/mL) | Immediately before next administration (Trough concentration) | |
Diazepam
|
Serum
0.5 |
S7P ↓ A00 |
|
3-5 |
HPLC KIMS (Kinetic Interaction of Microparticles in Solution) |
Diazepam 600-1000(ng/mL) | Immediately before the next administration (Trough concentration) However, when used as an antiepile | |
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
40.0-100.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.5 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
40.0-100.0(μg/mL) | Immediately before next administration (Trough concentration) | |
Clobazam
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(ng/mL) | ||
Nitrazepam
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
20-200(ng/mL) | Immediately before the next administration (Trough concentration) However, when used as an antiepile | |
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
10-40(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.5 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
10-40(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
10.0-20.0(μg/mL) | Oral: Immediately before the next dose (Trough concentration) Intravenous: 2 to 4 hours after admini | |
|
Plasma
0.5 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
10.0-20.0(μg/mL) | Oral: Immediately before the next dose (Trough concentration) Intravenous: 2 to 4 hours after admini | |
|
Serum
0.3 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
5.0-12.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.3 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
5.0-12.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
50-100(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.5 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) KIMS (Kinetic Interaction of Microparticles in Solution) |
50-100(μg/mL) | Immediately before next administration (Trough concentration) | |
Trimethadione
|
Serum
0.5 |
S7P ↓ A00 |
(12 days) |
7-13 |
LC-MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
300-500(μg/mL) | ||
Zonisamide
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
latex agglutination method KIMS (Kinetic Interaction of Microparticles in Solution) |
10-30(μg/mL) | Immediately before next administration (Trough concentration) | |
Gabapentin
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(μg/mL) | ||
Lamotrigine
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
2.5-15(μg/mL) | Immediately before next administration (Trough concentration) | |
Topiramate
|
Plasma
0.3 |
PH5 ↓ A00 |
(21 days) |
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
5-20(μg/mL) | Immediately before next administration (Trough concentration) | |
Levetiracetam
|
Plasma
0.3 |
PH5 ↓ A00 |
(21 days) |
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
12-46(μg/mL) | Immediately before next administration (Trough concentration) | |
Stiripentol
|
Plasma
0.3 |
PH5 ↓ A00 |
(28 days) |
5-11 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(μg/mL) | ||
Brivaracetam
|
Plasma 0.3 |
PH5 ↓ A00 |
(28 days) |
3-9 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
(μg/mL) | Immediately before next administration (Trough concentration) | |
Rufinamide
|
Plasma
0.3 |
PN2,PN5 ↓ A00 |
(28 days) |
3-9 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(μg/mL) | ||
Perampanel
|
Plasma
0.3 |
PH5 ↓ A00 |
(28 days) |
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(ng/mL) | ||
Lacosamide
|
Plasma
0.3 |
PH5 ↓ A00 |
(28 days) |
3-5 |
LC/MS/MS KIMS (Kinetic Interaction of Microparticles in Solution) |
(μg/mL) | Immediately before next administration (Trough concentration) | |
Acetazolamide
|
Serum
0.3 |
S7P ↓ A00 |
|
3-9 |
HPLC KIMS (Kinetic Interaction of Microparticles in Solution) |
(μg/mL) | ||
|
Plasma
0.2 |
PH5 ↓ A00 |
|
HPLC KIMS (Kinetic Interaction of Microparticles in Solution) |
10-30(μg/mL) | Immediately before next administration (Trough concentration) | ||
|
Serum
0.2 |
S7P ↓ A00 |
|
HPLC KIMS (Kinetic Interaction of Microparticles in Solution) |
10-30(μg/mL) | Immediately before next administration (Trough concentration) | ||
|
Serum
1.0 |
S7P ↓ A00 |
(14 days) |
4-10 |
Ultrafiltration method EIA KIMS (Kinetic Interaction of Microparticles in Solution) |
5.0-15.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Serum
1.0 |
S7P ↓ A00 |
(14 days) |
4-10 |
Ultrafiltration method EIA KIMS (Kinetic Interaction of Microparticles in Solution) |
1.0-2.0(μg/mL) | Oral: Immediately before the next dose (Trough concentration) Intravenous: 2 to 4 hours after administration |